Kornimate/medical-research-clean huggingface dataset:
electromyographic evaluation of the efficacy of manual therapy in temporomandibular joint dysfunction.

Conditions: Temporomandibular Joint Dysfunction

Summary: individuals with temporomandibular joint dysfunction (tmd) may experience changes in muscle activation as a result of symptoms such as pain and limitation of movement. the aim of this study is to examine the efficacy of manual therapy electromyographically in patients with tmd.

tmd is a common condition in the community. it may occur due to factors such as trauma, stress, occlusal disorders. symptoms include pain, limitation in mouth opening, joint voice, postural and psychosocial disorders. tmd/rdc diagnostic criteria are used in the classification of tmd, and accordingly, it is stated that it may originate from the joint, disc and chewing muscles. in the treatment, conservative treatments such as patient education, manual therapy and exercises are applied first. manual therapy is an effective physiotherapy method on pain and muscle dysfunctions in musculoskeletal problems. in our study, electromyographic changes of masticatory muscles will be examined by applying manual treatment to the masticatory muscles and cervical region in myofascial tmd patients according to tmd/rc.

Eligibility criteria:
inclusion criteria: * no cognitive impairment * diagnosed with temporomandibular joint(tmj) dysfunction of myofascial origin, * volunteers aged 18-65 exclusion criteria: * malignancy and fracture of the cervical region and/or tmj * active infection * patients actively receiving cervical and/or tmj-related therapy

Keywords: temporomandibular joint dysfunction manual therapy emg maximal mouth opening
psilocybin-enhanced psychotherapy for methamphetamine use disorder

Conditions: Amphetamine-Related Disorders

Summary: this is a proof-of-concept randomized clinical trial of psilocybin-enhanced psychotherapy versus treatment-as-usual among individuals being treated for methamphetamine use disorder.

the trial will take place with individuals admitted to a residential rehabilitation treatment program. the treatment protocol will consist of 4 preparatory therapy visits, 2 psilocybin sessions (25-30mg), and 8 total integration therapy visits. primary aims assess acceptability, feasibility, and safety with a primary endpoint at the conclusion of the study intervention. an additional aim assesses preliminary efficacy for methamphetamine use disorder and overall functioning at follow-up assessments 60 and 180 days after discharge from the residential treatment program.

Eligibility criteria:
inclusion criteria: * united states military veteran * moderate to severe methamphetamine use disorder using the dsm-v diagnostic criteria * desire to cease or reduce methamphetamine use exclusion criteria: * have uncontrolled hypertension or clinically significant cardiovascular disease * history of seizure disorder in adulthood * cns metastases or symptomatic central nervous system (cns) infection * poorly controlled diabetes mellitus * taking certain medications that may interact with psilocybin * history of any primary persistent psychotic disorder, including schizophrenia, schizoaffective disorder, bipolar disorder with psychosis, major depressive disorder with psychosis, or schizophreniform disorder * history of bipolar i disorder * current eating disorder with active purging * history of hallucinogen use disorder * pregnant or breast feeding

Keywords: methamphetamine, stimulant, psilocybin, psychedelic, psychotherapy
colloid preload versus colloid coload during cesarean deliveries

Conditions: Anesthesia; Adverse Effect, Spinal and Epidural; Hypotension

Summary: the investigators aimed to compare the methods colloid preloading and colloid coloading in terms of the incidence of maternal hypotension and impacts on neonatal outcomes. the second aim while planning the present study is to identify the method of the lowest adverse event for mother and infant and the simplest approach for the clinician.

spinal anesthesia (sa) is currently the most preferred method of anesthesia in elective cesarean deliveries. however, sa causes maternal hypotension by decreasing systemic vascular resistance over sympathetic blockade. maternal hypotension can lead to serious adverse events both in mother and in fetus: fetal hypoxia and acidosis occur due to decreased uterine blood flow, whereas the mother may experience vertigo, nausea, vomiting, alteration in consciousness, cardiovascular collapse and arrest. today, various strategies have been suggested for the prevention of maternal hypotension. of these strategies, the most critical ones are fluid load before spinal anesthesia (preloading) or rapid fluid load just after spinal anesthesia (coloading) and the use of vasopressor agent. the fluids used for this purpose include crystalloids and colloids. comparative studies performed with colloid preloading, colloid coloading and crystalloid coloading indicated that the incidence of hypotension decreased similarly with no significant difference determined between the methods of fluid loading. researchers defended necessity of using vasopressor agent together with fluid loading methods. in daily routine; however, the investigators observe that the incidence of hypotension is lower in the patients that undergo colloid preloading as compared to the patients that undergo colloid coloading or crystalloid coloading. the investigators therefore aimed to compare the methods colloid preloading and colloid coloading in terms of the incidence of maternal hypotension and impacts on neonatal outcomes. in the present study, the investigators aimed to use 6% hes 130/0.4 (voluven ®), which is the newer generation colloid solution. the other aim while planning the present study is to identify the method of the lowest adverse event for mother and infant and the simplest approach for the clinician.

Eligibility criteria:
inclusion criteria: * age 18 years or older * singleton pregnancy * gestational age ≥ 37 weeks * height ≥ 150 cm and ≤ 180 cm * weight \> 50 kg and \< 100 kg exclusion criteria: * gestational age \> 37 weeks * multiple pregnancies * fetal distress * preeclampsia * cardiovascular disease and diabetes * hematological problems * local infection at intervention site * abnormal coagulation tests * anticoagulant use * starch allergy * height \ 180 cm * weight \ 100 kg

Keywords: colloid preloading colloid coloading
autohypnosis and cancerology

Conditions: Colorectal Cancer; Breast Cancer

Summary: therapeutical hypnosis is proven to be an effective medical support to chemotherapy: it was shown that it can reduce the pain, anxiety, fatigue felt by the patient. yet, hypnosis requires the presence of an hypnotherapist, which is why auto-hypnosis could be an efficient alternative to handle the side effects of chemotherapy. in this study, colorectal cancer and breast cancer patients are either taught auto-hypnosis or are taken in standard care for their chemotherapy. the life quality score (qlqc30) assessed during and after chemotherapies will determine if auto-hypnosis is a good medical support in chemotherapies' adverse effects management. the proven benefices of auto-hypnosis in the handling of the side effects of chemotherapies could improve the quality of life of cancer affected patients.


Eligibility criteria:
inclusion criteria: * age superior or equal to 18 years old * colorectal or breast cancer history, treated by surgery and that should undergo an adjuvant chemotherapy * in the case of breast cancer, adjuvant chemotherapy must involve anthracyclines * ecog performance score \< 3 * patient must be affiliated or beneficiary of social security or any similar regime exclusion criteria: * patients already included in another interventional clinical research protocol * patients unable to proceed to hypnosis treatment due to their speech limitations (poor comprehension and expression of french, deafness, mental illness) * patients protected by french law from clinical inclusion ( pregnant, in labour, breastfeeding, legally protected, under judiciary or administrative liberty deprivation...)

Keywords: cancer autohypnosis quality of life
the effect of botulinum toxin injection at hip adductor muscles in patients with spastic cerebral palsy, pilot study

Conditions: Cerebral Palsy

Summary: in children with cerebral palsy, secondary problems lead to hip dislocation. the purpose of this study is to find out the effects of botulinum toxin a on hip joint dislocation in cerebral palsy patients.

* design: prospective study * inclusion criteria of patient group: who has a cerebral palsy and gmfcs level 3,4,5 * intervention: applied medication botulinum a injection (meditox 200unit) * main outcome measures: the investigators will measure for finding evidence by checking the x-ray photograph, hip adductor and muscles pressure test and electromyography(emg test) test of hip adductor, abductor and spine muscles.

Eligibility criteria:
inclusion criteria: * severe cerebral palsy patients(gmfcs level 3,4,5) * 2 to 10 years old exclusion criteria: * those who disagree with the study. * other than cerebral palsy.

Keywords: hip dislocation gmfcs level 3,4,5
limited access protocol for the use of oral cisapride

Conditions: Gastroparesis

Summary: due to the lack of other drugs to treat gastroparesis janssen and fda approved the compassionate use of cisapride to treat patients who had no other effective therapy. for this observational study, 3 patients who had already been prescribed cisapride by outside physicians, were followed to determine the effectiveness of cisapride on their gastric emtpying.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of gastroparesis. exclusion criteria: * no diagnosis of gastroparesis.
investigation of 9 consecutive infusions of remicade for psoriatic arthritis in austria (study p04264)

Conditions: Arthritis, Psoriatic

Summary: this is a prospective, open-label, 1-arm, multicenter observational study to determine the dose and time interval of remicade (infliximab) infusions in psoriatic arthritis (psa).

this study population was chosen from a non-probability sample.

Eligibility criteria:
inclusion criteria: * participants with active and progressive psoriatic arthritis who have responded inadequately to disease-modifying anti-rheumatic drugs. exclusion criteria: * all according to contraindications in the label especially: * participants with tuberculosis or other severe infections such as sepsis, abscesses, and opportunistic infections. * participants with moderate or severe heart failure (nyha class iii/iv). * participants with a history of hypersensitivity to infliximab or to other murine proteins, or to any of the excipients.
identify clinical conditions that increase circulating dna levels

Conditions: Pregnancy; Pulmonary Embolism; Myocardial Infarction; Autoimmune Disease

Summary: the investigators are developing a test that is expected to measure the amount of radiation a patient has been exposed to after a nuclear bomb. the investigator will do this by measuring the dna in the patients blood from cells killed by the radiation. many diseases and medical conditions can put dna in the blood. the investigator needs to know how much dna in order to better interpret our radiation detection test. therefore, the investigator is collecting blood from several patients with different diseases or medical conditions and also healthy volunteers to measure their dna content. patients that will be included in this study are pregnant women, patients who have suffered a pulmonary embolism within the past 48 hours, patients who have suffered from myocardial infarction in the past 48 hours, patients with autoimmune diseases and health patients.

the investigator will collect 8 ml (one and one half teaspoons) of blood one time only. the investigator may also collect the patient's past medical history, test results and disease treatment.

Eligibility criteria:
inclusion criteria: 1. patients must be adults in one of the following categories: * pregnant * suffered a pulmonary embolism within the past 48 hours * myocardial infarction in the past 48 hours * diagnosed with an autoimmune disease * adults age 18-80 * self-declared healthy adults 2. patients must be willing to undergo a blood draw 3. patients must provide study-specific informed consent prior to study entry exclusion criteria: 1. patients not meeting the above inclusion criteria

Keywords: pregnancy pulmonary embolism myocardial infarction autoimmune disease healthy controls
adaptive decision support for addiction treatment (adapt) factorial trial

Conditions: Opioid Use Disorder; Clinical Decision Support

Summary: this study is stage 1 of a larger study which refines and optimizes the embed\* clinical decision support (cds; see nct03658642) to increase number of ed physicians following standard of care for the administration of buprenorphine to appropriate patients with opioid use disorder. this study does not have open enrollment. investigators will use a multiphase optimization strategy (most) framework study with preparation, optimization, and confirmatory phases. in the current project, optimization phase, stage1 investigators will conduct a 2x2x2 factorial trial in which they expand embed to include sustainable implementation strategies: nurse prompt for withdrawal assessment, and targeted clinician prompt to use the cds along with patient resources to promote equity and motivate readiness to start treatment. later study phases will include optimization phase, stage 2: rapid-cycle randomized testing, and evaluation phase: a randomized trial of the optimized package compared to the original embed and the evaluation phase in which investigators will compare the efficacy of the optimized, multicomponent cds package to the original embed cds on ed-initiation of buprenorphine rates in patients with oud in a randomized trial. \*embed is a user centered, clinician facing clinical decision support system integrated into the electronic health record workflow to facilitate initiating buprenorphine in the emergency department by: diagnosing opioid use disorder with a checklist based on the diagnostic criteria of the dsm-5 (diagnostic and statistical manual of mental disorders, fifth edition), assessing the severity of withdrawal with the clinical opioid withdrawal scale (cows), motivating patients to accept treatment with a scripted brief negotiation interview, and automating the electronic health record workflow, including clinical and after visit documentation, order entry, prescribing, and referral for ongoing treatment in the community


Eligibility criteria:
inclusion criteria: * emergency department patient * 18 years of age or older * moderate to severe opioid use disorder exclusion criteria: * under 18 years of age * pregnant * currently receiving medication for opioid use disorder

Keywords: opioid use disorder clinical decision support
the role of influenza as a trigger for acute myocardial infarction: a caliber study

Conditions: Myocardial Infarction; Influenza

Summary: the purpose of this study is to examine the incidence of acute myocardial infarction (mi) occurring after an influenza-like illness using linked primary care and disease registry databases.

this study will measure the incidence ratio for mi occurring in time periods after presentation with an acute respiratory illness compared to baseline time periods using the self-controlled case series method, with reference to the timing of the influenza season (defined by national virological and clinical surveillance data). it will also validate accuracy and completeness of information on mi in the gprd using linked anonymised data from both minap and hospital episode statistics. this study is part of the caliber (cardiovascular disease research using linked bespoke studies and electronic records) programme funded over 5 years from the nihr and wellcome trust. the central theme of the caliber research is linkage of the myocardial ischaemia national audit project (minap) with primary care (gprd) and other resources. the overarching aim of caliber is to better understand the aetiology and prognosis of specific coronary phenotypes across a range of causal domains, particularly where electronic records provide a contribution beyond traditional studies. caliber has received both ethics approval (ref 09/h0810/16) and ecc approval (ref ecc 2-06(b)/2009 caliber dataset).

Eligibility criteria:
inclusion criteria: * participants must be registered with a gprd 'up to standard' practice during the study period 01/01/1999-31/12/2008 * they must have a record of an incident myocardial infarction (defined by a read codelist submitted to and agreed by gprd) that occurs both within their registration and the study period * they must have at least 6 months between their registration date and the date of the incident mi * they must have accessed primary care on at least one occasion for a respiratory illness during the study period exclusion criteria: * not fulfilling above criteria

Keywords: influenza, human influenza, human/complications myocardial infarction/etiology cardiovascular diseases/mortality
prevention of postoperative delirium with donepezil

Conditions: Cognitively Normal Elderly Individuals

Summary: patients undergoing hip or knee joint replacement at the age of 70 years or above who are cognitively unimpaired will receive donepezil or matching placebo before (over 5-7 days), during and after (over 7 days) surgery. the incidence of delirium will be monitored at 3 days, 7 days, and 49 days following surgery. we hypothesize that the incidence of delirium can be lowered from 20 per cent to 10 per cent by the intervention.


Eligibility criteria:
inclusion criteria: * cognitively healthy, elective hip or knee replacement exclusion criteria: * ongoing cholinergic treatment, dementia, delirium, acute physical illness

Keywords: delirium prevention donepezil
correlation of clitoral hood and labia minora measurements and female genital self image scale (fgsis) scores in women

Conditions: Genital Diseases, Female; Vulva

Summary: to evaluate the relationship between women's labium minora and clitoral hood measurements and female genital self image scale (fgsis) scores.

the main purpose of our study is to measure the labium minora and clitoral hood in women who apply to our clinic with gynecological disorders, evaluate them with fgsis (female genital self image scale) scores, and look at the relationship between genital area perception and labium minora and clitoral hood dimensions.

Eligibility criteria:
inclusion criteria: * women who apply for outpatient gynecological control, are between the ages of 18-45, are sexually active, do not have additional endocrinological or malignant diseases, and are not pregnant or in menopause. exclusion criteria: * those who are not sexually active, have varying degrees of pelvic organ prolapse or urinary incontinence, have a malignancy, or have an endocrinological disease

Keywords: genital diseases, vulva
collection of bone marrow from donors treated with or without filgrastim

Conditions: Healthy Stem Cell Donor; No Evidence of Disease

Summary: this randomized clinical trial is studying the side effects of collection of bone marrow from donors treated with or without filgrastim. giving colony-stimulating factors, such as filgrastim (g-csf), to donors helps the stem cells move from the bone marrow to the blood so they can be collected and stored.

primary objectives: i. to evaluate short- and long-term toxicities in bone marrow donors treated with vs without filgrastim before harvest. ii. to compare 10-year mortality and cancer in donors treated with vs without filgrastim. secondary objectives: i. to correlate the incidence of acute and chronic graft-vs-host disease in the marrow recipients enrolled on cog-asct0631 with four parameters assessed in the bone marrow harvests: absolute t-cell numbers, th1 vs th2 profile of t-cells, dendritic cell populations, and t-regulatory cell content. outline: donors are randomized to 1 of 2 treatment arms. arm i (unstimulated harvest): donors undergo conventional (i.e., unstimulated) bone marrow harvest on day 0. arm ii (stimulated harvest): donors receive filgrastim subcutaneously on days -4 through 0. donors then undergo bone marrow harvest on day 0. after completion of study treatment, donors are followed up at 1, 6, and 12 months and then annually for up to 10 years.

Eligibility criteria:
inclusion criteria: * appropriately human leukocyte antigen (hla)-matched (hla, a, b, drb1 identical or antigen mismatched \[i.e., 5/6 or 6/6 antigens matched\]) sibling of the bone marrow recipient enrolled on cog-asct0631 * adequate size relative to the recipient (i.e., harvesting the maximum of 20 cc/kg from the donor would result in a bone marrow graft that will provide an adequate cell and volume dose to the recipient, in the opinion of the treating physician) * enrolled on the cog umbrella long-term follow-up study cog-alte05n1 * not pregnant or nursing * no human immunodeficiency virus (hiv) positivity * no sickle cell trait or sickle cell anemia/disease * not at an increased risk from bone marrow donation after filgrastim administration due to a pre-existing medical condition, as determined by an independent physician separate from the research team * none of the following: * active infection, especially pulmonary * splenomegaly or a history of splenic injury * active or recent pulmonary disease (i.e., pneumonia within the past 4 weeks) * a condition that would make the donor unsuitable to donate, as determined by an independent physician separate from the research team * no autoimmune disease